Fidelity Investments’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-48,741
| Closed | -$904K | – | 5742 |
|
|
2023
Q3 | $904K | Buy |
48,741
+4,585
| +10% | +$51.9K | ﹤0.01% | 2477 |
|
|
2023
Q2 | $488K | Buy |
44,156
+180
| +0.4% | +$2.51K | ﹤0.01% | 2669 |
|
|
2023
Q1 | $591K | Sell |
43,976
-206
| -0.5% | -$3.56K | ﹤0.01% | 2638 |
|
|
2022
Q4 | $547K | Sell |
44,182
-890,196
| -95% | -$12.6M | ﹤0.01% | 2692 |
|
|
2022
Q3 | $13M | Sell |
934,378
-1,132,128
| -55% | -$18.2M | ﹤0.01% | 1785 |
|
|
2022
Q2 | $28.5M | Sell |
2,066,506
-271,486
| -12% | -$4.35M | ﹤0.01% | 1505 |
|
|
2022
Q1 | $38M | Sell |
2,337,992
-140,830
| -6% | -$2.21M | ﹤0.01% | 1502 |
|
|
2021
Q4 | $40.4M | Sell |
2,478,822
-87,608
| -3% | -$1.48M | ﹤0.01% | 1508 |
|
|
2021
Q3 | $38.1M | Sell |
2,566,430
-10,042
| -0.4% | -$161K | ﹤0.01% | 1538 |
|
|
2021
Q2 | $51.5M | Sell |
2,576,472
-292,579
| -10% | -$5.8M | ﹤0.01% | 1412 |
|
|
2021
Q1 | $66.2M | Sell |
2,869,051
-628,560
| -18% | -$17.5M | 0.01% | 1258 |
|
|
2020
Q4 | $86.4M | Sell |
3,497,611
-230,307
| -6% | -$7.63M | 0.01% | 1096 |
|
|
2020
Q3 | $155M | Sell |
3,727,918
-1,093,387
| -23% | -$50.2M | 0.02% | 734 |
|
|
2020
Q2 | $231M | Sell |
4,821,305
-50,159
| -1% | -$3.87M | 0.03% | 558 |
|
|
2020
Q1 | $307M | Buy |
4,871,464
+13,018
| +0.3% | +$1.17M | 0.04% | 373 |
|
|
2019
Q4 | $602M | Buy |
4,858,446
+5,567
| +0.1% | +$498K | 0.07% | 273 |
|
|
2019
Q3 | $322M | Buy |
4,852,879
+4,663
| +0.1% | +$313K | 0.04% | 454 |
|
|
2019
Q2 | $386M | Buy |
4,848,216
+394,946
| +9% | +$35.3M | 0.05% | 405 |
|
|
2019
Q1 | $498M | Buy |
4,453,270
+5,100
| +0.1% | +$557K | 0.06% | 310 |
|
|
2018
Q4 | $448M | Buy |
4,448,170
+13,468
| +0.3% | +$1.4M | 0.06% | 310 |
|
|
2018
Q3 | $560M | Sell |
4,434,702
-2,630
| -0.1% | -$278K | 0.06% | 294 |
|
|
2018
Q2 | $372M | Buy |
4,437,332
+661,542
| +18% | +$48.4M | 0.04% | 415 |
|
|
2018
Q1 | $232M | Buy |
3,775,790
+10,490
| +0.3% | +$632K | 0.03% | 625 |
|
|
2017
Q4 | $220M | Buy |
3,765,300
+1,010
| +0% | +$63.7K | 0.03% | 649 |
|
|
2017
Q3 | $218M | Buy |
3,764,290
+13,612
| +0.4% | +$1.47M | 0.03% | 646 |
|
|
2017
Q2 | $454M | Buy |
3,750,678
+25,958
| +0.7% | +$3.01M | 0.06% | 335 |
|
|
2017
Q1 | $421M | Buy |
3,724,720
+3,404
| +0.1% | +$397K | 0.05% | 384 |
|
|
2016
Q4 | $404M | Buy |
3,721,316
+12,360
| +0.3% | +$1.47M | 0.05% | 377 |
|
|
2016
Q3 | $610M | Buy |
3,708,956
+18,932
| +0.5% | +$2.98M | 0.08% | 257 |
|
|
2016
Q2 | $526M | Buy |
3,690,024
+29,128
| +0.8% | +$4.25M | 0.07% | 291 |
|
|
2016
Q1 | $470M | Buy |
3,660,896
+11,168
| +0.3% | +$1.32M | 0.07% | 315 |
|
|
2015
Q4 | $545M | Buy |
3,649,728
+19,404
| +0.5% | +$3.28M | 0.07% | 280 |
|
|
2015
Q3 | $602M | Buy |
3,630,324
+19,478
| +0.5% | +$4.28M | 0.09% | 249 |
|
|
2015
Q2 | $872M | Buy |
3,610,846
+27,760
| +0.8% | +$7.39M | 0.11% | 190 |
|
|
2015
Q1 | $1.01B | Buy |
3,583,086
+379,135
| +12% | +$82.1M | 0.13% | 167 |
|
|
2014
Q4 | $500M | Buy |
3,203,951
+21,258
| +0.7% | +$3.93M | 0.07% | 339 |
|
|
2014
Q3 | $753M | Buy |
3,182,693
+10,745
| +0.3% | +$2.74M | 0.1% | 219 |
|
|
2014
Q2 | $751M | Buy |
3,171,948
+282,679
| +10% | +$74.5M | 0.1% | 213 |
|
|
2014
Q1 | $953M | Buy |
2,889,269
+225,289
| +8% | +$76M | 0.13% | 163 |
|
|
2013
Q4 | $182M | Buy |
2,663,980
+296,359
| +13% | +$17.1M | 0.03% | 675 |
|
|
2013
Q3 | $163M | Buy |
2,367,621
+368,152
| +18% | +$18.2M | 0.03% | 712 |
|
|
2013
Q2 | $89.7M | Buy |
+1,999,469
| New | +$68.3M | 0.01% | 965 |
|
Fidelity Investments's ICPT Position: Q4 2023 in Review
Fidelity Investments sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 48,741 shares — an estimated $904K sold.
Fidelity Investments first reported a position in ICPT in Q2 2013 and held it in 42 quarters. The position peaked at $1.01B in Q1 2015. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.
- Fidelity Investments reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
- Fidelity Investments sold 48,741 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $904K.
- Fidelity Investments first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2013 and held it in 42 quarters.
- Fidelity Investments's Intercept Pharmaceuticals, Inc. position peaked at $1.01B in Q1 2015.
- 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.
Based on Fidelity Investments's 13F filing for Q4 2023, filed 13 Feb 2024.